Stocks of SQZ Biotechnologies Company (NYSE:SQZ) traded higher last session on Wall Street, down -2.32% to $0.73.
According to the data, SQZ Biotechnologies Company (NYSE:SQZ) has 4 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $34.00 and a low of $4.00, we find $7.00. Given the previous closing price of $0.75, this indicates a potential upside of 833.33 percent. SQZ stock price is now -48.91% away from the 50-day moving average and -73.40% away from the 200-day moving average. The market capitalization of the company currently stands at $21.34M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A total of 1 analysts have issued a hold rating and 3 have given it a buy rating. Brokers who have rated the stock have averaged $13.00 as their price target over the next twelve months.
On November 24, 2020, Stifel recently initiated its ‘Buy’ rating on the stock quoting a target price of $38, while ‘BTIG Research’ rates the stock as ‘Buy’.
In other news, Capasso Richard, insider sold 1,183 shares of the company’s stock on Aug 15. The stock was sold for $3,935 at an average price of $3.33. Upon completion of the transaction, the insider now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 25, Director Jensen Klavs F. bought 14,326 shares of the business’s stock. A total of $50,428 was incurred on buying the stock at an average price of $3.52. This leaves the insider owning 353,309 shares of the company worth $0.26 million. Insiders disposed of 1,183 shares of company stock worth roughly $863.59 over the past 1 year. A total of 1.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SQZ stock. A new stake in SQZ Biotechnologies Company shares was purchased by PARAMETRIC PORTFOLIO ASSOCIATES LLC during the first quarter worth $37,000. BALYASNY ASSET MANAGEMENT LLC invested $9,000 in shares of SQZ during the first quarter. In the first quarter, TOWER RESEARCH CAPITAL LLC (TRC) acquired a new stake in SQZ Biotechnologies Company valued at approximately $8,000. BNP PARIBAS ARBITRAGE, SNC acquired a new stake in SQZ for approximately $3,000. AMALGAMATED FINANCIAL CORP. purchased a new stake in SQZ valued at around $2,000 in the second quarter. In total, there are 72 active investors with 68.70% ownership of the company’s stock.
Tuesday’s opening bell rang with an opening price of $0.7600 for SQZ Biotechnologies Company (NYSE: SQZ). During the past 12 months, SQZ Biotechnologies Company has had a low of $0.65 and a high of $8.21. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.50, and a quick ratio of 3.50. The fifty day moving average price for SQZ is $1.4288 and a two-hundred day moving average price translates $2.7442 for the stock.
The latest earnings results from SQZ Biotechnologies Company (NYSE: SQZ) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.78, missing analysts’ expectations of -$0.77 by -0.01. This compares to -$0.80 EPS in the same period last year. The company reported revenue of $3.45 million for the quarter, compared to $4.75 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -27.4 percent. For the current quarter, analysts expect SQZ to generate $4.25M in revenue.
SQZ Biotechnologies Company(SQZ) Company Profile
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
